Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED | N.MMED.WA | N.MMED.WR | N.MMED.WS

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by ferdie1on May 18, 2011 10:32am
270 Views
Post# 18593404

RE: RE: We could use Good Grades = String of Pearl

RE: RE: We could use Good Grades = String of PearlEver watch the DOT convert a two lane HWY to a four lane? Well traffic has to stop in both directions in the short term. In the engineering business it is called contingency re-routing. They processed LG which was much better than NG. This transition will see the U/G produce up to 1,200 tpd while reducing the OP contribution. In addition, services (air & water, electrics, and discharge lines had to be resized & re-installed).

Stanley:

You seem to defend shortcomings quite a bit, I've been in engineering nearly 30 years and worked on projects from the artic circle to the rain forests in brazil and I never heard the term "contingency re-routing", (contingency is a term for if things go wrong whats the back-up) the new ramp replaced the old ramp, services were installed in the new ramp as well in the new 4.5m dia fresh air raise, so the services were in thru the raise before the ramp was finished, the problem with this whole thing was a super aggressive schedule which APG had convinced BRD could be accomplished, the pit had to effectively stop while the new decline was being established.  The original decline and FAR was in the middle of the phase 2 pit strip.

I don't see the grade control issue vanishing as now they have to "learn" how to follow the ore u/g which you should know from your experience is a bit more challenging than pit grade control given the history of the carb zone. Once they get into the flow ore it will be much easier to follow.

So in short, failure of BRD to scrutinize the APG plan at time of "purchase" is the root cause for this failure to launch so far. Will things improve, of course they will, RA is too smart a guy to let this turn into a dog, hopefully by the 3rd quarter we will see a consistent gold stream. Don't buy into this stock if you expect overnight turnarounds.

DYODD

Bullboard Posts